To assess the antitumoral efficacy of systemically dosed exoASO-STAT6 in HCC, we used the Hepa1-6 orthotopic model (Fig. 5A) The treatment was initiated 3 days after tumor inoculation. This evidence concerns the gene STAT6 and hepatocellular carcinoma.